Drugs / Omega
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01858948 | Jul 2013 → Apr 2018 | — | University of Cincinnati | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01660932 Comparator | Mar 2011 → Aug 2012 | hypertriglyceridemia | Gachon University Gil Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omega | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01858948 ↗ |
| Known as | EPA+DHA supplements (OmegaRx) | “EPA+DHA supplements (OmegaRx)” NCT01858948 ↗ |
| Modality | Other / unclassified | “long-chain omega-3 (LCn-3) fatty acid supplementation” NCT01858948 ↗ |